

Amendments to the Claims

Please amend the claims presently pending in the application and add new claims 30 and 31 as shown below in the list of claims.

List of Claims

1-16. Cancelled.

17. (Previously presented) A peptide with ferroxidase activity consisting essentially of the amino acid sequence of SEQ ID NO:7. ✓
18. (Currently amended) ~~The peptide of claim 17, wherein said peptide is 23 amino acids in length~~ A peptide comprising the amino acid sequence of SEQ ID NO:7, wherein said peptide has ferroxidase enzymatic activity. ✓
19. (Previously presented) The peptide of either claim 17 or claim 18, wherein said peptide is substantially pure. ✓
20. (Currently amended) A pharmaceutical composition ~~in unit dose form~~ comprising a ~~therapeutically effective amount of~~ the peptide of either claim 17 or claim 18, together with a pharmaceutically acceptable carrier.
21. (Currently amended) The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is in unit dose form and comprises 0.01-10 mg of said peptide.
22. (Previously presented) The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is in the form of a liquid suitable for parenteral administration.

23. (Currently amended) The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is indicated for use in ~~the treatment of~~ reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury or for administration to a patient undergoing surgery to reduce cellular injury resulting from oxidative stress.
24. (Previously presented) A peptide with ferroxidase activity consisting of the amino acid sequence of SEQ ID NO:7.
25. (Previously presented) The peptide of claim 24, wherein said peptide is substantially pure.
26. (Currently amended) A pharmaceutical composition ~~in unit dose form~~ comprising a ~~therapeutically effective amount of~~ the peptide of claim 24, together with a pharmaceutically acceptable carrier.
27. (Currently amended) The pharmaceutical composition of claim 26, wherein said pharmaceutical composition is in unit dose form and comprises 0.01-10 mg of said peptide.
28. (Previously presented) The pharmaceutical composition of either claim 26 or claim 27, wherein said pharmaceutical composition is in the form of a liquid suitable for parenteral administration.
29. (Currently amended) The pharmaceutical composition of claim 28, wherein said pharmaceutical composition is indicated for use in ~~the treatment of~~ reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury, or for administration to a patient before surgery to reduce cellular injury resulting from oxidative stress.

30. (New) A pharmaceutical composition in unit dose form comprising the peptide of either claim 17 or claim 18 together with a pharmaceutically acceptable carrier, wherein said peptide is present in a therapeutically effective amount for reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury, or for administration to a patient undergoing surgery to reduce cellular injury resulting from oxidative stress.
31. (New) A pharmaceutical composition in unit dose form comprising the peptide of claim 24 together with a pharmaceutically acceptable carrier, wherein said peptide is present in a therapeutically effective amount for reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury, or for administration to a patient undergoing surgery to reduce cellular injury resulting from oxidative stress.